Compare Stocks: RNAZ, PMN, BDTX, and COYA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.93 -0.5%	$1.97	$1.60 ▼ $4.94	$110.88M	3.31	1.06 million shs	662,811 shs
COYA Coya Therapeutics	$4.76 +6.7%	$4.62	$3.71 ▼ $7.75	$111.67M	0.61	181,943 shs	221,477 shs
PMN Promis Neurosciences	$13.20 +2.5%	$13.91	$6.27 ▼ $27.40	$118.40M	-0.24	100,878 shs	21,800 shs
RNAZ TransCode Therapeutics	$1.67 -0.6%	$4.30	$1.58 ▼ $20.99	$28.28M	1.16	120,883 shs	58,150 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-1.52%	-7.62%	-5.37%	+16.87%	-38.80%
COYA Coya Therapeutics	-4.09%	-3.25%	-4.50%	-9.35%	-21.34%
PMN Promis Neurosciences	-0.08%	-10.31%	-12.14%	+22.20%	+21.51%
RNAZ TransCode Therapeutics	+3.44%	-7.02%	-47.63%	-64.79%	-85.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.93 -0.5%	$1.97	$1.60 ▼ $4.94	$110.88M	3.31	1.06 million shs	662,811 shs
COYA Coya Therapeutics	$4.76 +6.7%	$4.62	$3.71 ▼ $7.75	$111.67M	0.61	181,943 shs	221,477 shs
PMN Promis Neurosciences	$13.20 +2.5%	$13.91	$6.27 ▼ $27.40	$118.40M	-0.24	100,878 shs	21,800 shs
RNAZ TransCode Therapeutics	$1.67 -0.6%	$4.30	$1.58 ▼ $20.99	$28.28M	1.16	120,883 shs	58,150 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-1.52%	-7.62%	-5.37%	+16.87%	-38.80%
COYA Coya Therapeutics	-4.09%	-3.25%	-4.50%	-9.35%	-21.34%
PMN Promis Neurosciences	-0.08%	-10.31%	-12.14%	+22.20%	+21.51%
RNAZ TransCode Therapeutics	+3.44%	-7.02%	-47.63%	-64.79%	-85.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	2.64	Moderate Buy	$10.25	431.09% Upside
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	222.13% Upside
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	157.58% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNAZ, PMN, BDTX, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/8/2026	PMN Promis Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
8/6/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	BDTX Black Diamond Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	$70M	1.58	$0.52 per share	3.74	$1.97 per share	0.98
COYA Coya Therapeutics	$7.95M	14.05	N/A	N/A	$2.06 per share	2.31
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.58) per share	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	$22.37M	-$0.75	N/A	N/A	N/A	N/A	-32.10%	-25.21%	11/5/2026 (Estimated)
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)

Latest RNAZ, PMN, BDTX, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million
8/5/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.1954	-$0.17	+$0.0254	-$0.17	$5.56 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	7.28	7.28
COYA Coya Therapeutics	N/A	13.40	13.40
PMN Promis Neurosciences	N/A	7.85	7.85
RNAZ TransCode Therapeutics	N/A	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
COYA Coya Therapeutics	39.75%
PMN Promis Neurosciences	50.13%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	9.29%
COYA Coya Therapeutics	6.10%
PMN Promis Neurosciences	1.50%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	21	57.45 million	52.12 million	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
PMN Promis Neurosciences	11	8.97 million	8.83 million	Not Optionable
RNAZ TransCode Therapeutics	12	16.93 million	16.91 million	Not Optionable

RNAZ, PMN, BDTX, and COYA Headlines

Recent News About These Companies

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

September 16 at 9:00 PM | seekingalpha.com

Join Today’s Live Investor Webinar with TransCode Therapeutics

September 16 at 12:35 PM | usatoday.com

TransCode Therapeutics Announces Leadership Transition

September 10, 2026 | prnewswire.com

Join TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

September 3, 2026 | usatoday.com

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

August 31, 2026 | prnewswire.com

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7, 2026 | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

April 27, 2026 | prnewswire.com

TransCode Therapeutics signs financing deal worth up to $20 million

April 8, 2026 | msn.com

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

April 7, 2026 | prnewswire.com

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

March 3, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, PMN, BDTX, and COYA Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$1.93 -0.01 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 0.00 (-0.26%)

As of 05:26 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Coya Therapeutics NASDAQ:COYA

$4.76 +0.30 (+6.73%)

Closing price 04:00 PM Eastern

Extended Trading

$4.76 0.00 (0.00%)

As of 04:10 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Promis Neurosciences NASDAQ:PMN

$13.20 +0.32 (+2.48%)

Closing price 03:59 PM Eastern

Extended Trading

$13.21 +0.01 (+0.08%)

As of 04:10 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

TransCode Therapeutics NASDAQ:RNAZ

$1.67 -0.01 (-0.59%)

Closing price 03:59 PM Eastern

Extended Trading

$1.70 +0.03 (+2.09%)

As of 04:10 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, PMN, BDTX, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, PMN, BDTX, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, PMN, BDTX, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, PMN, BDTX, and COYA Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Coya Therapeutics NASDAQ:COYA

Promis Neurosciences NASDAQ:PMN

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, PMN, BDTX, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, PMN, BDTX, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, PMN, BDTX, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, PMN, BDTX, and COYA Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Coya Therapeutics NASDAQ:COYA

Promis Neurosciences NASDAQ:PMN

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools